Close menu

March 6th, 2023 | 14:15 CET

Alibaba, Alpina Holdings, NIO - Buy Asian stocks now?

  • RealEstate
  • Investments
  • Electromobility
  • ecommerce
Photo credits:

The ECB has so far failed to keep pace with the US in terms of interest rate hikes. The reward for this was inflation of 8.7% in Germany in January. The value is expected to remain at this level in February. The Federal Statistical Office recently made changes to the shopping basket and used 2020 instead of 2015 as the base year for the calculation. The high energy prices, especially in Germany, are causing great uncertainty in industry. BASF has already decided to invest several billion euros in China. There have been positive impulses for the economy from China since the easing of the Corona measures. An economic upswing could be imminent here. Reason enough to take a closer look at three companies from Asia.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    Uwe Ahrens, Director, Altech Advanced Materials AG
    "[...] We know exactly what we are doing and are implementing what we consider to be a proven technology in an industrially applicable and scalable way. [...]" Uwe Ahrens, Director, Altech Advanced Materials AG

    Full interview


    Alibaba - Analyst estimates exceeded

    Alibaba is a major player in China's e-commerce and cloud computing markets, falling from its highest market valuation of USD 835 billion to around USD 230 billion. On February 23, the Company reported revenue of USD 35.9 billion for Q3 FY2023, up 2% YOY, thanks mainly to BABA International Commerce, which posted an 18% YOY increase, and Cainiao, which posted a 27% YOY increase in revenue.

    Cloud segment revenue growth was primarily driven by healthy public cloud growth, partially offset by declining hybrid cloud revenue. However, overall growth continues to slow. A significant portion of Alibaba Cloud's revenue comes from non-web industries, particularly financial services, education, and automotive, which accounted for 53% of total revenue. After capital expenditures of USD 850 million, the Company generated free cash flow of USD 11.8 billion, which was used, among other things, to repurchase about 45 million shares.

    The group thus beat analysts' estimates on sales by USD 40 million and non-GAAP earnings per share by USD 0.39. Operating income was up about 400%, and net income more than doubled from a year ago. Fundamentally, the stock is cheap. As an investor, however, one should be aware that since the critical statements of its founder Jack Ma towards the Chinese government, obstacles have repeatedly been put in the way of the group. Those aware of the risk can buy at a share price of currently USD 89.70. The price should not fall below the support level of USD 85.04 on a closing price basis.

    Alpina Holdings - 3% dividend yield

    Alpina Holdings operates in Singapore and provides real estate and construction services to its clients, mainly from the public sector. Its business model is based on three divisions: integrated building services (IBS), mechanical and electrical (M&E) engineering services, and alterations and additions (A&A). As the Company holds the highest licenses in Singapore, it can participate in all tenders issued by public institutions. With its subsidiary Digo Corporation, it has made progress in the renewable energy sector and will install solar cells with a capacity of 70 MWp by 2025.

    On February 24, the Company released its unaudited annual results for 2022, reporting total revenue of SGD 49.89 million and a net profit of SGD 2.04 million. The Company declared a total dividend of SGD 0.5424 per share for the fiscal year. Despite the negative impact of increased labour and subcontracting costs on the overall gross margin, Alpina's three business segments remained operationally profitable. The Group generated 8 new contracts that run until the end of 2028 and have a total value of SGD 10.45 million. As of December 31, cash and cash equivalents amounted to SGD 11.66 million.

    The Company also secured the "Certified Facilities Management Company" certification. This should make Alpina even more competitive in the future. In the coming years, Singapore's Building and Construction Authority (BCA) expects annual orders of SGD 14 and 18 billion from the public sector. Growth potential is therefore available, and the 3% dividend yield is impressive - especially as the management has confirmed to distribute at least 50% of the Company's profit to shareholders in the coming years. The Alpina Holdings share is currently listed at SGD 0.18 and can also be traded in Frankfurt.

    NIO - Disappointing in the short term, better prospects long term

    NIO is a Chinese manufacturer of electric vehicles (EVs) and suffered on the stock market after the release of its latest figures. The earnings report showed shrinking profit margins and lower short-term revenue expectations than expected, disappointing many investors. Revenue for the fourth quarter of 2022 came in at USD 2.33 billion, down USD 230 million from expectations but up 62.2% YOY. Total revenue for 2022 was USD 7.14 billion, up 36.3% YOY. Vehicle sales totalled USD 2.14 billion, up 60.2% YOY.

    The main criticism is the significantly shrunken vehicle margin, which fell from over 20% to just 6.8%. The reasons cited for this were the switch to new product lines, the reluctance of buyers to wait for the new models, and greater competition. The latest generation models are expected to start shipping in Q2 with higher margins. The fact is that Tesla also had to lower its prices in China recently. William Li, CEO of NIO, expects the margin to be back between 18 to 20% by the end of 2023.

    Analysts at Deutsche Bank and Bank of America were surprised by the low margin and adjusted their price targets downward. In the short term, there could be further pressure after the Q1 figures. The last sales figures in February were 12,157 vehicles, which is still an increase of almost 100% YOY. In the long term, the turnaround could start after the Q2 figures. Currently, one should still be cautious because the chart looks battered. The support level at USD 8.38 has been held. Currently, one pays USD 9.57 for a share certificate.

    In Asia, the economy is on the rise. Alibaba has positively surprised analysts. Fundamentally, the stock is cheap but carries political risks. NIO has surprised analysts negatively, but the long-term outlook could be good. Here, one should wait for the figures for the 2nd quarter. There are no political problems in Singapore. Alpina Holdings has been operating successfully there for 17 years. The Company pays out 50% of its profits, which currently corresponds to a dividend yield of about 3%.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Nico Popp on September 28th, 2023 | 09:05 CEST

    Germany - Car Country? The exodus begins: Mercedes-Benz, Volkswagen, First Phosphate

    • Mining
    • phosphate
    • Electromobility
    • Energy

    Cars still play a significant role in Germany. Many households have two vehicles, some even more. However, sales of new cars have weakened recently - the question of whether to buy a combustion engine or an electric vehicle, along with inflation, have deterred many buyers. German brand manufacturers are now being attracted to the US. There, they are enticed by subsidies and an intact market. Find out what the latest plans of Mercedes-Benz, Volkswagen, and others entail and which relatively unknown company could benefit.


    Commented by Fabian Lorenz on September 28th, 2023 | 07:10 CEST

    BYD unstoppable. Sell Varta shares? 200% with Almonty Industries?

    • Mining
    • Tungsten
    • Electromobility
    • renewableenergies

    Electromobility and the energy transition offer numerous investment opportunities along the value chain. Take BYD, for example. The Chinese company is increasingly becoming the e-car market leader. Could they soon even dethrone Tesla? That should make the stock interesting. And what about Varta? The battery manufacturer disappointed investors last year. Is the stock attractive now? Analysts continue to take a critical view of the Company. Almonty Industries is a different story. After the latest half-year figures, the experts at Sphene Capital advise buying. From 2024, sales and profits of the tungsten producer are expected to grow strongly. According to the analysts, the share could triple.